Juvista (Avotermin) in Breast Reduction Surgery Scars

Inclusion Criteria: * Female patients between 18 and 65 years of age undergoing bilateral reduction mammaplasty with anchor shaped incisions, who have given written informed consent. * Patients with a Body Mass Index of 15-32 kg/m2 inclusive. * Patients of child bearing potential who are using method(s) of contraception acceptable to the Investigator and agree to do so from at least the screening visit until 1 month after administration of the trial investigational products. * Patients with, in the opinion of the Investigator, clinically acceptable results for the laboratory tests specified in the trial protocol. Exclusion Criteria: * Patients with significant breast asymmetry that may result in asymmetrical operative incisions being made on the left and rights breasts. * Patients with breast asymmetry that may result in different post-operative tensions on the wounds of the left and right breasts. * Patients who have had surgery in the area to be incised within one year of trial surgery. * Patients with a history of a bleeding disorder. * Patients with a history of breast malignancy. * Patients with a skin disorder that is chronic or currently active and which the Investigator considers will adversely affect the healing of the wounds or involves the areas to be examined in this trial. * Patients who on direct questioning and/or physical examination, have evidence of any past or present clinically significant medical condition that would impair wound healing. * Patients with a history of clinically significant hypersensitivity to any of the drugs or surgical dressings to be used in this trial. * Patients who are taking, or have taken, any investigational drugs in the 3 months prior to the screening visit. * Patients who are taking regular, continuous, oral corticosteroid therapy. * Patients undergoing investigations or changes in management for an existing medical condition. * Patients who are or who become pregnant up to and including the day of surgery or who are lactating. * Patients with diseases or conditions that could, in the opinion of the Investigator, interfere with the assessment of safety or efficacy of the investigational product. * Patients who, in the opinion of the Investigator, are not likely to complete the trial.